# Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma

> **NCT07224100** · PHASE2 · RECRUITING · sponsor: **University of Washington** · enrollment: 33 (estimated)

## Conditions studied

- B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
- B Lymphoblastic Leukemia/Lymphoma With t(9;22)(q34.1;q11.2); BCR-ABL1
- Lymphoblastic Lymphoma

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Doxorubicin
- **DRUG:** Etoposide
- **BIOLOGICAL:** Filgrastim
- **BIOLOGICAL:** Pegfilgrastim
- **DRUG:** Ponatinib
- **DRUG:** Prednisone
- **BIOLOGICAL:** Rituximab
- **DRUG:** Vincristine
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bone Marrow Aspiration
- **PROCEDURE:** Bone Marrow Biopsy
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Positron Emission Tomography

## Key facts

- **NCT ID:** NCT07224100
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-30
- **Primary completion:** 2028-07-31
- **Final completion:** 2028-07-31
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2026-04-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07224100

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07224100, "Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07224100. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*